Maridebart cafraglutide
Also known as: AMG 133, AMG-133, MariTide
Classification
Peptide
Regulatory Status
Overview
Maridebart cafraglutide combines GLP-1 receptor agonism with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism in an antibody-peptide conjugate format (per Phase 2 trial BACKGROUND).
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
ClassB source cannot establish canonical regulatory or safety fields. The statements below are retained as uncertainty, not as a label-backed verdict. | Regulatory status: investigational | Contraindication: Not approved for clinical use outside authorized trials | Warning: Investigational only — GI adverse events (nausea, vomiting, constipation) were common in Phase 2; long-term and outcomes safety not established | Adverse effect: nausea | Adverse effect: vomiting | Adverse effect: constipation | Serious adverse effect: not fully characterized outside trial context
Pathways
Interactions & cautions
Drug interactions
other GLP-1 or dual-incretin agonists — Class overlap with incretin therapies (GI effects, delayed gastric emptying context) is expected; no approved interaction table exists yet. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.